GlassScriptPhysician profile
Sanjay Michael Salgado
NPI 1861874174
$34,985.96
in general payments reported to CMS, 2019-2025
29 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $16K · 2023: $2,081 · 2024: $2,481 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $13K · Food and Beverage: $4,748 · Travel and Lodging: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $12,500.00 |
| Food and Beverage | $4,747.98 |
| Travel and Lodging | $1,262.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $29,195.97 | 2021-2025 | General - Therapies, Apollo Esg System, Nxt Tissue Helix Pro |
| Ovesco Endoscopy USA, INC. | $909.69 | 2024 | |
| Apollo Endosurgery US INC | $651.15 | 2023 | Overstitch Endoscopic Suturing System |
| Abbvie INC. | $520.42 | 2022-2025 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $463.17 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Conmed Corporation | $375.38 | 2023 | Conmed Biliary, Conmed Generators, Conmed Hemostasis |
| Medtronic, INC. | $297.28 | 2022-2025 | Nexpowder |
| Qol Medical, LLC | $274.57 | 2024-2025 | Sucraid, Sucraid |
| Mauna Kea Technologies, INC. | $260.16 | 2023 | |
| Gilead Sciences, INC. | $249.73 | 2022-2024 | Livdelzi |
| Janssen Biotech, INC. | $210.21 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Phathom Pharmaceuticals, INC. | $184.27 | 2024-2025 | Voquezna |
| Genzyme Corporation | $178.19 | 2025 | |
| Ferring Pharmaceuticals INC. | $171.22 | 2022-2024 | Rebyota |
| Janssen Scientific Affairs, LLC | $138.25 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $135.30 | 2025 | Rezdiffra |
| Ardelyx, INC. | $126.29 | 2023-2025 | Ibsrela |
| Pfizer INC. | $123.40 | 2024-2025 | |
| Erbe USA INC | $116.31 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.63 | 2024-2025 | Entyvio |
| Amgen INC. | $68.35 | 2023-2025 | Amjevita, Avsola, Uplizna |
| Lilly USA, LLC | $67.29 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $35.98 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $33.68 | 2024-2025 | |
| Sanofi US Services INC. | $21.33 | 2025 | |
| Sanofi Pasteur INC. | $20.67 | 2025 | |
| Braintree Laboratories, INC. | $18.28 | 2024 | Suflave |
| Aimmune Therapeutics, INC. | $15.13 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $14.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Salgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.